BiotechTube
VivoSim

VivoSim

San Francisco, United States· Est.
vivosim.ai
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

VivoSim is a San Francisco-based biotech providing New Approach Methodology (NAM)-based toxicology services to de-risk drug development. Its core offering is the NAMkind™ platform, which utilizes primary human cells to create 3D micro-liver and micro-intestine organoids for predictive safety screening. The company targets three key decision points in the drug pipeline: prospective screening during hit-to-lead, translational bridging before IND-enabling studies, and investigative toxicology for unexpected findings. By offering human-relevant data, VivoSim aims to reduce reliance on animal models and prevent costly late-stage drug failures due to toxicity.

Small Molecules

Technology Platform

NAMkind™ platform utilizing primary human cells to create customizable 3D micro-liver and micro-intestine organoids for predictive toxicology screening, supported by a modular assay portfolio.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

Strong regulatory and industry push towards New Approach Methodologies (NAMs) and reducing animal testing creates a favorable market environment.
High cost of late-stage drug failures due to toxicity drives demand for better predictive tools early in R&D.
Potential to expand service offerings to other tissue types or integrate deeper AI/ML-driven data analysis.

Risk Factors

Risk that the NAMkind™ models may not achieve full predictive validation or widespread regulatory acceptance compared to traditional methods.
Competition from other organoid/NAM startups and large, established CROs developing similar capabilities.
Execution risk in scaling a bespoke service business and maintaining scientific quality while growing.

Competitive Landscape

VivoSim competes in the preclinical CRO and organoid technology space. Direct competitors include other startups offering complex *in vitro* toxicology models (e.g., Emulate, CN Bio, Hepregen). It also faces competition from large, full-service CROs (e.g., Charles River, Labcorp) that are incorporating more human-based models into their offerings. Differentiation hinges on the specificity of its liver/intestine models, customization, and integrated expert analysis.

More companies in Small Molecule Drugs →More companies in United States →